1-3 of 3
Manuela Lazzari
Close
Sort by
Journal Articles

Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma

Clinical Trials & Observations
Alessandro Rambaldi, Manuela Lazzari, Cristina Manzoni, Emanuela Carlotti, Luca Arcaini, Michele Baccarani, Tiziano Barbui, Carlo Bernasconi, Giuseppe Dastoli, Giovanna Fuga, Enrica Gamba, Livio Gargantini, Valter Gattei, Francesco Lauria, Mario Lazzarino, Franco Mandelli, Enrica Morra, Alessandro Pulsoni, Michela Ribersani, Pier Luigi Rossi-Ferrini, Maurizio Rupolo, Sante Tura, Vittorina Zagonel, Francesco Zaja, PierLuigi Zinzani, Gigliola Reato, Robin Foa
Journal: Blood
Blood (2002) 99 (3): 856–862.
https://doi.org/10.1182/blood.V99.3.856
Published: 2002
Journal Articles

CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59

Josée Golay, Manuela Lazzari, Valeria Facchinetti, Sergio Bernasconi, Gianmaria Borleri, Tiziano Barbui, Alessandro Rambaldi, Martino Introna
Journal: Blood
Blood (2001) 98 (12): 3383–3389.
https://doi.org/10.1182/blood.V98.12.3383
Published: 2001
Journal Articles

Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis

Josée Golay, Luisella Zaffaroni, Thomas Vaccari, Manuela Lazzari, Gian-Maria Borleri, Sergio Bernasconi, Francesco Tedesco, Alessandro Rambaldi, Martino Introna
Journal: Blood
Blood (2000) 95 (12): 3900–3908.
https://doi.org/10.1182/blood.V95.12.3900
Published: 2000